Author

Patrick Joseph Worth

Oregon Health & Science UniversityORCID 0000-0001-9600-0678Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

Rosalie C. SearsiD· 4 shared Carl PelziD· 3 shared Colin J. DanieliD· 3 shared Jennifer R. EngiD· 3 shared Jonathan Robert BrodyiD· 3 shared Motoyuki TsudaiD· 3 shared Ellen M. LangeriD· 2 shared Ethan S. AgritelleyiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Rosalie C. SearsORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 29, 2026

Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells

Kevin Hawthorne, Jennifer R. Eng, Motoyuki Tsuda…·Rosalie C. Sears

The paper identifies subtype-intermediate progenitor cells in pancreatic cancer with distinct epigenetic profiles linked to clinical outcomes and lineage reprogramming.

DOI 10.64898/2026.09.28.754674

humanscATAC-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 15, 2025

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

Motoyuki Tsuda, Dove J. Keith, Colin J. Daniel…·Rosalie C. Sears

The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.

DOI 10.64898/2025.12.12.693851

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer Research CommunicationsPeer-reviewedNov 24, 2025

MicroCT enables simultaneous longitudinal tracking of murine pancreatic cancer progression and cachexia

Katherine R. Pelz, Philip Jimenez, Colin J. Daniel…·Teresa A. Zimmers

This paper introduces a dual-contrast microCT protocol to track tumor growth, metastasis, and cachexia in murine PDAC models over time.

1 citation

mouseimaging

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 14, 2025

Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model

Isabel A. English, Patrick Joseph Worth, Kevin Hawthorne…·Rosalie C. Sears

This study develops a novel pancreatic cancer mouse model by expressing Myc and mutant Kras in adult acinar cells, showing metastasis and therapeutic resistance similar to human PDAc.

5 citations

mouseexperimental assay

𝕏 PostBluesky